子宫内膜异位症大鼠模型的建立及其病理学改变

目的构建子宫内膜异位症（内异症）大鼠动物模型,为阐明内异位症发病机理以及寻找有效的治疗方法提供理想的动物模型。方法取性成熟雌性Sprague-Dawley（SD）大鼠30只,通过手术将大鼠自体子宫组织移植到子宫旁韧带上,建立诱发型内异症大鼠动物模型。术后8周,再次剖腹观察异位组织的存活情况、病灶大小、与周围组织的粘连程度以及病理学变化。结果25只大鼠有明显的异位病灶。所有病灶都与周围组织有不同程度的粘连,病灶外观呈囊泡状。光镜观察见大部分异位子宫内膜形态和结构与在位子宫内膜基本相同,但内膜细胞、间质细胞、腺体,与在位内膜相比较少。少数病灶只有上皮组织或只有问质组织。结论自体子宫移植法可成功建立内异症大鼠模型。     

大鼠子宫异位症模型建立方法的比较

目的将自体子宫内膜组织同时种植于大鼠体内三个不同部位,建立的子宫内膜异位症模型进行比较评估。方法取30只雌性未交配性成熟大鼠,将自体子宫内膜组织种植于左侧腹壁、子宫卵巢韧带和右侧皮下筋膜层与腹壁肌层间,术后第21天取出异位组织,进行组织形态学观察。结果异位内膜可以在大鼠不同部位同时生长,体积和重量均无显著性差异,其种植成功率差异不显著（93%-100%）,且种植物组织形态相似。结论此手术方法建立的大鼠子宫内膜异位症模型异位内膜病理改变与EMs患者类似,但皮下种植更简单,更直观,可减小损伤,便于反复实验及连续性观察研究。     

注射法小鼠皮下子宫内膜异位症模型及组织学观察

目的 建立ICR小鼠皮下子宫内膜异位症新的模型及组织学观察.方法 以同系小鼠作为供体,取子宫内膜分别采用皮下注射法和皮下植入法对2组共24只小鼠行皮下造模手术.3周后测量皮下种植结节大小,并处死半数造模成功小鼠,取子宫和异位结节行HE染色组织学研究.6周后,处死剩余小鼠,并再次测量皮下结节,取子宫和异位结节行HE染色组织学研究.结果 皮下植入法和皮下注射法成功率分别为33.33%和83.33%(P<0.01);生长良好的囊肿囊内壁有内膜上皮细胞生长,有与正位子宫内膜接近同步的发情周期改变;病灶随移植时间的推延先逐渐增大之后又有缩小趋势(P>0.05).结论 将ICR小鼠子宫内膜注射到同系小鼠腹部皮下形成子宫内膜异位病理模型,成功率高,且简单可行,异位内膜随动情周期有周期性改变,生理特性与正位子宫内膜基本相同,应用于子宫内膜异位症疾病和药物研究既经济又稳定可靠.     

人子宫内膜异位症裸鼠模型的建立

目的建立人子宫内膜异位症裸鼠模型。方法通过开腹手术方法将人子宫内膜组织块种植于裸鼠盆腹腔,观察其生长情况,并进行病理检查。结果成功建立人子宫内膜异位症裸鼠模型,种植病灶能保持原有内膜组织的形态结构,并可见血管生成明显。结论子宫内膜异位症裸鼠模型的建立是子宫内膜异位症早期临床研究的理想模型。     

改良大鼠子宫内膜异位症模型的建立及微血管密度观察

目的对皮下筋膜层与腹壁肌层之间移植自体子宫内膜制作的子宫内膜异位症（endometriosis,EMs）模型进行评估。方法取10只雌性未交配性成熟大鼠,术前雌激素诱导,手术开腹取右侧子宫,将自体子宫内膜种植于双侧皮下筋膜层与腹壁肌层之间,术后第29天取出异位组织,进行组织形态学观察,免疫组织化学染色观察微血管密度（Microvessel density,MVD）。结果异位内膜在腹壁内生长,呈隆起囊状小包块,内有黏液,具有正常子宫内膜基本组织结构。异位内膜中微血管密度较在位内膜和正常子宫内膜高。结论此手术方法建立的大鼠子宫内膜异位症模型异位内膜病理改变与EMs患者类似,可以作为子宫内膜异位研究的动物模型。     

内皮抑素转基因治疗子宫内膜异位症大鼠模型的实验研究

目的:了解内皮抑素(ES)转基因治疗子宫内膜异位症大鼠模型的疗效。方法:构建子宫内膜异位症大鼠模型,选择建模成功的大鼠为实验研究对象,随机分为ES转染组(I组)24只、载体对照组(Ⅱ组)20只和阴性对照组(Ⅲ组)20只。I组病灶局部注射lipofectamine-endo-pBud复合物进行基因转染,Ⅱ组注射lipofectamine-pBud复合物,Ⅲ组注射PBS用于对照。通过实时荧光定量PCR法检测异位病灶中ES基因的相对表达量,用Western-blot测定ES-HA融合蛋白及ES蛋白的相对表达量,来判断转染成功与否。用ELISA法对大鼠血清中ES及血管内皮细胞生长因子(VEGF)水平进行测定,用免疫组化SP法对ES、基质金属蛋白酶-2(MMP-2)以及微血管密度(MVD)的表达进行测定,用游标卡尺对转染前后各组大鼠异位病灶的长、宽进行测量,计算体积,分析各指标实验前后的差异,观察内皮抑素转基因治疗子宫内膜异位症大鼠模型的疗效。结果:注射相应试剂后2周,I组异位病灶组织中ES基因的相对表达量高于两对照组(P<0.05),有ES-HA融合蛋白表达,且ES蛋白的相对表达量显著高于两对照组(P<0.01);I组血清中ES水平显著高于两对照组(P<0.01),VEGF水平显著低于两对照组(P<0.01),三组ES与VEGF在血清中的表达水平呈负相关(r=-0.805);I组异位病灶组织中ES表达明显高于两对照组(P<0.01);MMP-2的表达明显少于两对照组(P<0.01);MVD明显少于两对照组(P<0.01);三组ES与MMP-2在异位内膜中的表达呈负相关(r=-0.700);I组异位病灶体积明显小于两对照组(P<0.01)。结论:阳离子脂质体LipofectamineTM2000介导的重组质粒endo-pBud病灶内直接注射法可以成功实现ES在子宫内膜异位症大鼠异位内膜中的表达,并对子宫内膜异位症大鼠模型有治疗作用。     

非动情期SD大鼠子宫内膜异位症模型的建立

目的　研究SD大鼠非动情期子宫内膜异位症建立方法和异位病灶的组织学形态及体液免疫反应。方法　采用外科诱导法对 40只非动情期和 40只动情期SD雌性大鼠行子宫组织自体移植手术。采集造模前后的血液进行体液免疫IgG、IgA、IgM、C3 、C4 的观察 ;手术后 7周取健侧子宫中段的在位内膜和移植的异位内膜行组织学研究。结果　SD大鼠非动情期进行子宫组织自体异位种植术成模率 95% ,与大鼠动情期进行子宫组织自体异位种植术成模率 94 8%比较 ,二者差异无显著性 ;异位内膜上皮细胞功能活跃 ,有类似正位子宫内膜的周期变化 ,其生理特征与正位子宫内膜基本相同。且造模后大鼠体液免疫反应敏感IgG、C3 增高 (P <0 0 1、3 P <0 0 5) ;IgM降低 (P <0 0 1)、IgA、C4 差异无显著性。结论　SD大鼠非动情期和动情期进行子宫组织自体异位种植术均可建立良好的子宫内膜异位症模型     

ERβ对子宫内膜异位症小鼠模型的影响

目的通过建立子宫内膜异位症小鼠模型探讨雌激素β受体对子宫内膜异位症的影响。方法利用雌激素β基因敲除小鼠建立自体子宫内膜异位模型;应用人不同的组织在SCID小鼠建立子宫内膜异位症模型后,注射雌激素β受体激动剂WAY-200070,观察其对异位病灶生长的影响。结果比较30只雌激素β受体基因敲除小鼠及22只同源未敲除小鼠异位病灶生长及组织细胞形态无明显差异（P〉0.05）;雌激素β受体激动剂WAY-200070对不同类型的SCID小鼠内异症病灶生长影响无明显差异（P〉0.1）。结论雌激素β受体对子宫内膜异位病灶的形成影响作用微弱。     

子宫内膜异位症对小鼠生育能力的影响

目的建立子宫内膜异位症小鼠模型,观察子宫内膜异位症对模型小鼠妊娠能力的影响。方法通过"腹腔+皮下"同系异体子宫内膜注射法建立子宫内膜异位症小鼠模型,与假手术组、空白组比较,观察其妊娠率及活胎率,观察子宫内膜异位症对模型小鼠妊娠能力的影响。结果建模2周后,小鼠皮下和腹腔均见有子宫内膜异位病灶生成,模型组、假手术组和空白组,共三组。通过生育功能检测,三组妊娠率差异有显著性意义(P0.05)。三组的活胎数差异有显著性意义(P0.05)。结论成功建立子宫内膜异位症小鼠模型,并证实子宫内膜异位症可影响模型小鼠生育功能。     

内皮抑素转基因治疗子宫内膜异位症大鼠模型的实验研究

目的：了解内皮抑素（ES）转基因治疗子宫内膜异位症大鼠模型的疗效。方法：构建子宫内膜异位症大鼠模型,选择建模成功的大鼠为实验研究对象,随机分为ES转染组（I组）24只、载体对照组（Ⅱ组）20只和阴性对照组（Ⅲ组）20只。I组病灶局部注射lipofectamine-endo-pBud复合物进行基因转染,Ⅱ组注射lipofectamine-pBud复合物,Ⅲ组注射PBS用于对照。通过实时荧光定量PCR法检测异位病灶中ES基因的相对表达量,用Western-blot测定ES-HA融合蛋白及ES蛋白的相对表达量,来判断转染成功与否。用ELISA法对大鼠血清中ES及血管内皮细胞生长因子（VEGF）水平进行测定,用免疫组化SP法对ES、基质金属蛋白酶-2（MMP-2）以及微血管密度（MVD）的表达进行测定,用游标卡尺对转染前后各组大鼠异位病灶的长、宽进行测量,计算体积,分析各指标实验前后的差异,观察内皮抑素转基因治疗子宫内膜异位症大鼠模型的疗效。结果：注射相应试剂后2周,I组异位病灶组织中ES基因的相对表达量高于两对照组（P〈0.05）,有ES-HA融合蛋白表达,且ES蛋白的相对表达量显著高于两对照组（P〈0.01）;I组血清中ES水平显著高于两对照组（P〈0.01）,VEGF水平显著低于两对照组（P〈0.01）,三组ES与VEGF在血清中的表达水平呈负相关（r=-0.805）;I组异位病灶组织中ES表达明显高于两对照组（P〈0.01）;MMP-2的表达明显少于两对照组（P〈0.01）;MVD明显少于两对照组（P〈0.01）;三组ES与MMP-2在异位内膜中的表达呈负相关（r=-0.700）;I组异位病灶体积明显小于两对照组（P〈0.01）。结论：阳离子脂质体LipofectamineTM2000介导的重组质粒endo-pBud病灶内直接注射法可以成功实现ES在子宫内膜异位症大鼠异位内膜中的表达,并对子宫内膜异位症大鼠模型有治疗作用。     

Structural and histomorphometric evaluations of ferutinin effects on the uterus of ovariectomized rats during osteoporosis treatment

AimsThe effects of chronic administration of Ferutinin (phytoestrogen found in the plants of genus Ferula), compared with those elicited by estradiol benzoate, were evaluated, following ovariectomy, on the uterus of ovariectomized rats as regard weight, size, structure and histomorphometry.Main methodsThe experimental study included 40 female Sprague–Dawley rats, assigned to two different protocols, i.e. preventive and recovering. In the preventive protocol, ferutinin (2 mg/kg/day) was orally administered for 30 days, starting from the day after ovariectomy; in the recovering protocol, ferutinin was administered, at the same dosage, for 30 days starting from the 60th day after ovariectomy, when osteoporosis was clearly established. Its effects were compared with those of estradiol benzoate (1.5 μg per rat twice a week, subcutaneously injected) vs. vehicle-treated ovariectomized controls and vehicle-treated sham-operated controls. Uteri were removed, weighed and analysed under both the structural and histomorphometrical points of view.Key findingsOur data show that ferutinin acts, similarly to estradiol benzoate, on the uterus stimulating endometrial and myometrial hypertrophy; this notwithstanding, the phytoestrogen ferutinin, in contrast to estrogen treatment, appears to increase apoptosis in uterine luminal and glandular epithelia.SignificanceFerutinin, used in osteoporosis treatment primarily for bone mass recovering, seems in line with an eventual protective function against uterine carcinoma, unlike estrogens so far employed in hormone replacement therapy (HRT).     

Facilitation of female sexual behavior in male rats by septal lesions: an interaction with estrogen.

Although destruction of the septal region markedly facilitates the lordosis behavior of female rats in response to estrogen priming, comparable lesions were found to be ineffective in facilitating the lordotic behavior of estrogen primed male rats. Neither the age at the time of septal destruction nor castration influenced the lordosis behavior of males. However, if prepubertal castrated males were given subcutaneous ovarian grafts or injected daily with 2 μgm estradiol benzoate (EB) during the 30 day period following septal destruction, a prolonged facilitation of the activational effects of EB on lordosis behavior was observed. Male rats subjected to septal destruction alone, chronic exposure to EB alone, exposure to ovarian grafts for 30 days prior to septal destruction, or chronic treatment with EB started 6 mo after septal lesioning, failed to show an increase in behavioral responsiveness to estrogen. Thus, in order for septal lesions to facilitate lordosis behavior of male rats, exposure to EB or ovarian tissue must occur within an apparent critical period following septal destruction. Adult male rats were found to be more responsive to this interaction of septal lesions and EB exposure than pubertal animals. It is suggested that the prolonged facilitation of lordosis behavior which follows septal destruction and estrogen exposure in the male rat may be due to hormonal modifications of the recovery process following brain damage.     

Induction of Cytosolic Progestin Binding Sites by Catecholestrogens in Rat Pituitary Gland and Uterus: Different Potencies of 2- and 4-Hydroxyestradiol

The ability of catecholestrogens to induce cytosolic progestin binding sites in the hypothalamus, pituitary gland, and uterus of ovariectomised-adrenalectomised rats was demonstrated by the increase in high-affinity [3H]promegestone binding sites (KD 1.39, 0.50, and 0.54 nM, respectively) following a single subcutaneous injection (26.4 micrograms/animal) of the 3.4-dibenzoate ester of 4-hydroxyestradiol. The affinity and the time course of induction of these binding sites were very similar to those after a single injection of an equivalent dose (20 micrograms/animal) of estradiol 3-benzoate, exhibiting maximal receptor levels after 44 h. Widely differing efficacies in the induction of progestin binding sites were observed between the dibenzoate esters of 2- and 4-hydroxyestradiol. 2-Hydroxyestradiol 2,3-dibenzoate was ineffective in the pituitary gland up to a dose of 132 micrograms/animal, whereas 4-hydroxyestradiol dibenzoate was equipotent to estradiol benzoate, showing a maximal induction of progestin binding sites at single doses in the range of 13.2-26.4 micrograms/animal (equivalent to 10-20 micrograms of estradiol benzoate). As compared to the pituitary gland, the uterus was much more sensitive to the systemic administration of estrogen benzoates. At single doses in the range of 1.32-6.6 micrograms/animal (equivalent to 1-5 micrograms of estradiol benzoate), 4-hydroxyestradiol dibenzoate induced maximal levels of progestin receptors, and even 2-hydroxyestradiol dibenzoate, when given at a high dose (132.4 micrograms/animal, equivalent to 100 micrograms of estradiol benzoate), produced a slight increase in progestin binding sites.     

LH discharge induced by medial preoptic implantation of estrone or dopamine in the ovariectomized estradiol primed rat.

Effect of implantation of estrogens or catecholamines into the medial preoptic area through chronically implanted double cannula on the release of LH was examined in the ovariectomized estradiol-primed rat. Implantation of estrone at 12:00 on the second or third day after subcutaneous injection of estradiol benzoate (20 mug) increased the serum concentration of LH at 18:00 compared with that in the non-implanted controls, whereas implantation of estradiol benzoate on the third day did not affect it. Dopamine implantation at 12:00 on the third day also induced a significant increase of LH concentration at 18:00, and, in contrast, norepinephrine implantation decreased the concentration at 18:00. It may be said that the medial preoptic area is responsive to estrone and can induce LH release, whereas it is not to estradiol. Furthermore, dopamine was effective for the activation of the medial preoptic area in relation to the inducement of LH release.     

Changes in uterine estrogen receptor concentrations in persistent estrous and persistent diestrous rats

Changes in uterine weight and the estrogen receptor concentrations were examined in persistent estrous (PE) and persistent diestrous (PD) rats at 80 days of age. To prepare PE rats, 100 micrograms estradiol benzoate (EB) was injected sc into 3-day-old females. PD rats were obtained by daily injections of 10 micrograms EB into females for 10 consecutive days from the day of birth. The uterine weight in PE rats at 80 days was comparable to that in metestrous controls. The uteri of PD rats were smaller than those in PE rats. The concentrations of estrogen receptor in nuclear fractions in PE and PD rats were much lower than those in proestrous controls. Receptor concentrations in cytosol fractions were significantly lower in PE and PD rats than in control diestrous, proestrous and estrous rats. The dissociation constants and sedimentation coefficients of estrogen receptors in PE and PD rats were found to be in the same range as those in control rats. Thus, the reduction in the activity of cytosol receptors in these rats is attributable to a quantitative change in the amount of estrogen receptor protein. To study the response of the uterus to estrogen, ovariectomized rats were injected daily with 10 micrograms estradiol for 7 consecutive days. The uterine growth of PE and PD rats after administration of estradiol was less marked than in controls, indicating a reduction of estrogen sensitivity of the uterus. Seven daily administrations of estradiol continued to increase the concentration of uterine cytosol estrogen receptor in controls. In contrast, in PE and PD rats, the receptor concentrations continued to increase during the first 3 days, and then remained constant. These data suggest that EB in neonatal treatment may directly affect the mechanism of receptor synthesis in uterine tissues. This effect may contribute to the reduction of the uterine response to estrogen.     

Estrogenic effects of zearalenone on the expression of progestin receptors and sexual behavior in female rats

Zearalenone is a resorcylic acid lactone compound that is produced by fungal infection of edible grains and is believed to influence reproduction by binding to estrogen receptors. In order to study the potential estrogenic effects of this compound in the brain, we examined the effects of zearalenone on the expression of neuronal progestin receptors and feminine sexual behavior in female rats. Ovariectomized rats were treated with zearalenone (0.2, 1.0, or 2.0 mg), estradiol benzoate, or vehicle daily for 3 days. They were then either perfused, and progestin receptors visualized by immunocytochemistry, or injected with progesterone and tested for sexual receptivity with male rats. Progestin receptor-containing cells were counted in the medial preoptic area and ventromedial hypothalamus. The two highest doses of zearalenone increased the concentration of neuronal progestin receptors, as did 10 microg of estradiol. The highest dose of zearalenone (2 mg) also induced progestin receptor staining density comparable to that of 10 microg of estradiol benzoate. In behavioral tests, ovariectomized animals treated with 2 mg of zearalenone followed by progesterone showed levels of sexual receptivity comparable to females treated daily with estradiol benzoate (2 microg) followed by progesterone. These studies suggest that, although structurally distinct and less potent than estradiol, zearalenone can act as an estrogen agonist in the rat brain.     

Progesterone regulation of estrogen receptor in the rat uterus: A primary inhibitory influence on the nuclear fraction

The purpose of this study was to determine the short-term effects of progesterone action on estrogen receptor (Re) levels in the rat uterus. Ovariectomized, adrenalectomized rats were maintained on subcutaneous Silastic implants containing crystalline estradiol. Progesterone treatment with serum estradiol maintenance caused a rapid decrease (within 4 h) of total Re, attributable to loss of nuclear Re without a significant change in cytosol Re levels. Removal of estradiol implants resulted in an increase in total Re and cytosol Re at all time periods studied without a significant decrease in nuclear Re until 8 h. Combined estradiol withdrawal and progesterone treatment resulted in lower total Re levels and a more rapid decrease in nuclear Re than with estradiol withdrawal alone. These results demonstrate that progesterone rapidly and selectively decreases nuclear Re levels in rat uterus and suggest that this process is not dependent on cytosol Re or serum estradiol levels.     

Effects of dihydrotestosterone and estradiol benzoate pretreatment upon testosterone-induced sexual behavior in the castrated male rat

Three groups of inexperienced castrated male rats were treated daily for 15 days with oil, estradiol benzoate (1 μg), or dihydrotestosterone (1 mg), and thereafter injected daily with testosterone (1 mg) for 21 days. Sexual behavior was tested every third day after the start of the pretreatment until day 36. Estradiol benzoate or dihydrotestosterone failed to elicit sexual behavior. Pretreatment with dihydrotestosterone, but not estradiol benzoate, significantly shortened the intervals to initiation of mounting and intromission in response to testosterone. The results suggest that fully developed genitals (penis and/or sexual accessories) facilitate initiation of copulatory behavior in response to testosterone administration.     

Effect of neonatal exposure to the antioestrogens nafoxidine and CI-628 upon the development of the uterus in the prepubertal rat

Neonatal Sprague-Dawley rats were injected with the antioestrogens nafoxidine or CI-628 on Day 3 of life alone or in combination with oestradiol benzoate 24 h later. Oestrogen-stimulated glucose oxidation and cytoplasmic oestrogen binding sites of the uteri were assessed at 21-23 days of age. Neither antioestrogen antagonized the prepubertal uterine impairments produced by neonatal oestradiol treatment. Both antioestrogens administered alone produced deficits which mimicked those produced by neonatal oestrogenization. However, the agonist property of each antioestrogen was differentially expressed: treatment with CI-628 reduced prepubertal oestrogen binding sites in the uterus, but nafoxidine exposure decreased the sensitivity of the uterus to oestradiol stimulation of glucose oxidation. It is postulated that CI-628 directly affects the uterus to reduce production of oestrogen receptor protein, while nafoxidine affects the development of the uterine phosphogluconate oxidative pathway indirectly through impaired ovarian function. However, antioestrogens blocked the neonatal oestradiol-induced reduction in the oestrogen-stimulated production of actomyosin in the adult uterus. Therefore, while both CI-628 and nafoxidine are clearly agonists in the neonatal rat, each appears to exhibit cell-specific agonist and antagonist properties.     

The effect of intravenously administered prostaglandin E2 on rat uterine 3′, 5′-adenosine monophosphate

PGE₂ administered intravenously increased levels of cyclic AMP in uterine tissue of rats ovariectomized 12 days before treatment. This action of PGE₂ on uterine tissue was dose-dependent, with a dose response curve from 50 to 600 μ/Kg and the maximum effect was seen 10 minutes after PGE₂ administration. Delay of prostaglandin treatment until 25 days post-ovariectomy prevented this response. Administration of estradiol benzoate to such animals however, allowed the rat uterus to respond with elevated cyclic AMP levels at 3 minutes but not at 10 or 45 minutes after PGE₂ treatment.